S I Sherman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, 1400 Pressler Street, Unit 1461, Houston, TX 77030, USA
    Oral Oncol 49:707-10. 2013
  2. doi request reprint The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer
    Steven I Sherman
    University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Endocr Pract 19:157-61. 2013
  3. pmc Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca
    Marcia S Brose
    Department of Otorhinolaryngology Head and Neck Surgery, The University of Pennsylvania, Abramson Cancer Center, Clinical Research Building, Room 127, 425 Curie Boulevard, Philadelphia, PA 19104, USA
    BMC Cancer 11:349. 2011
  4. ncbi request reprint Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma
    S I Sherman
    Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Surg Oncol 16:12-5. 1999
  5. doi request reprint Cytotoxic chemotherapy for differentiated thyroid carcinoma
    S I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Clin Oncol (R Coll Radiol) 22:464-8. 2010
  6. doi request reprint Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Clin Endocrinol Metab 94:1493-9. 2009
  7. doi request reprint Motesanib diphosphate in progressive differentiated thyroid cancer
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77230 1402, USA
    N Engl J Med 359:31-42. 2008
  8. ncbi request reprint Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma 3:249-52. 2003
  9. doi request reprint Early clinical studies of novel therapies for thyroid cancers
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 435, Houston, TX 77030, USA
    Endocrinol Metab Clin North Am 37:511-24, xi. 2008
  10. ncbi request reprint Thyroid carcinoma
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Texas, Houston 77030, USA
    Lancet 361:501-11. 2003

Detail Information

Publications62

  1. doi request reprint Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, 1400 Pressler Street, Unit 1461, Houston, TX 77030, USA
    Oral Oncol 49:707-10. 2013
    ..To review studies of novel multitargeted kinase inhibitors studied in patients with medullary thyroid cancer (MTC)...
  2. doi request reprint The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer
    Steven I Sherman
    University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Endocr Pract 19:157-61. 2013
    ..To describe the evolving role of recombinant human thyrotropin in the diagnostic evaluation of patients treated for differentiated thyroid carcinoma...
  3. pmc Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca
    Marcia S Brose
    Department of Otorhinolaryngology Head and Neck Surgery, The University of Pennsylvania, Abramson Cancer Center, Clinical Research Building, Room 127, 425 Curie Boulevard, Philadelphia, PA 19104, USA
    BMC Cancer 11:349. 2011
    ..The DECISION trial was designed to assess the ability of sorafenib to improve PFS in patients with locally advanced or metastatic, radioactive iodine (RAI)-refractory DTC...
  4. ncbi request reprint Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma
    S I Sherman
    Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Surg Oncol 16:12-5. 1999
    ..Recommendations are provided to permit standardized approaches to clinicopathologic staging, and future research directions are identified...
  5. doi request reprint Cytotoxic chemotherapy for differentiated thyroid carcinoma
    S I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Clin Oncol (R Coll Radiol) 22:464-8. 2010
    ..Newer approaches to treatment as well as trial design and recruitment, emphasising the role of thyroid cancer patients in early drug trials, may yield advances in patient benefit...
  6. doi request reprint Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Clin Endocrinol Metab 94:1493-9. 2009
    ..For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, novel therapies are needed to improve disease outcomes...
  7. doi request reprint Motesanib diphosphate in progressive differentiated thyroid cancer
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77230 1402, USA
    N Engl J Med 359:31-42. 2008
    ..Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT...
  8. ncbi request reprint Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma 3:249-52. 2003
    ..Recommendations are provided for diagnosis and treatment of this syndrome...
  9. doi request reprint Early clinical studies of novel therapies for thyroid cancers
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 435, Houston, TX 77030, USA
    Endocrinol Metab Clin North Am 37:511-24, xi. 2008
    ..This article focuses on findings from key studies that reflect the new paradigms for treatment...
  10. ncbi request reprint Thyroid carcinoma
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Texas, Houston 77030, USA
    Lancet 361:501-11. 2003
    ....
  11. doi request reprint Targeted therapy of thyroid cancer
    Steven I Sherman
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1432, Houston, TX 77030, USA
    Biochem Pharmacol 80:592-601. 2010
    ..Alternative options now exist for use of tyrosine kinase inhibitors that are well tolerated and may prove worthy of regulatory approval for this disease...
  12. doi request reprint Targeted therapies for thyroid tumors
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 24:S44-52. 2011
    ..Alternative options now exist for use of tyrosine kinase inhibitors that are well tolerated and may prove worthy of regulatory approval for this disease...
  13. doi request reprint Molecularly targeted therapies for thyroid cancers
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Endocr Pract 15:605-11. 2009
    ..To review the emerging evidence that therapies targeting key oncogenic and signaling kinases can be effective in treatment of advanced thyroid carcinomas...
  14. ncbi request reprint Central hypothyroidism associated with retinoid X receptor-selective ligands
    S I Sherman
    Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 340:1075-9. 1999
    ....
  15. ncbi request reprint Adjuvant therapy and long-term management of differentiated thyroid carcinoma
    S I Sherman
    Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Surg Oncol 16:30-3. 1999
    ..An approach to long-term monitoring and therapy is provided, including the use of strategies dependent upon the extent of the patient's initial disease...
  16. doi request reprint Tyrosine kinase inhibitors and the thyroid
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, Division of Internal Medicine, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Best Pract Res Clin Endocrinol Metab 23:713-22. 2009
    ..Adverse effects on thyroid function and thyroid hormone metabolism have also been seen with several TKIs, necessitating prospective thyroid function testing for all patients starting therapy...
  17. doi request reprint Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience
    Maria E Cabanillas
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 95:2588-95. 2010
    ..In this paper, we describe the University of Texas M. D. Anderson Cancer Center's experience with the off-label use of these tyrosine kinase inhibitors for DTC...
  18. doi request reprint Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era
    David L Schwartz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 30:883-8. 2008
    ..The purpose of this study is to catalog modern-era postoperative radiotherapy (external beam radiotherapy [EBRT]) outcomes for advanced medullary thyroid cancer...
  19. ncbi request reprint Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients
    Tina W F Yen
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surgery 134:890-9; discussion 899-901. 2003
    ..The surgical management and follow-up strategy in patients with medullary thyroid carcinoma (MTC) remain controversial because of the lack of data on the natural history of these tumors and their patterns of progression...
  20. ncbi request reprint Preventable reoperations for persistent and recurrent papillary thyroid carcinoma
    Maria A Kouvaraki
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Surgery 136:1183-91. 2004
    ..This retrospective study was designed to determine the frequency of inadequate surgical or medical therapy as a cause of persistent or recurrent PTC...
  21. ncbi request reprint Prognostic factors in patients with Hürthle cell neoplasms of the thyroid
    Luis Lopez-Penabad
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1186-94. 2003
    ..The objective of the current study was to identify the clinical and pathologic features of Hürthle cell carcinomas that predict disease progression or death...
  22. ncbi request reprint Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer
    Bradley A Schiff
    Department of Head and Neck Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 10:8594-602. 2004
    ..Epidermal growth factor (EGF) has been shown to play a role in the pathogenesis of many types of cancer, and its receptor (EGFR) provides an attractive target for molecular therapy...
  23. doi request reprint Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer
    Mauricio A Moreno
    Department of Otolaryngology, Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, USA
    Arch Otolaryngol Head Neck Surg 137:157-62. 2011
    ..To evaluate the long-term outcomes and prognostic value of our sonographically based surgical approach to the lateral neck for recurrences in papillary thyroid cancer (PTC)...
  24. doi request reprint Four patients with cutaneous metastases from medullary thyroid cancer
    Libero Santarpia
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Thyroid 18:901-5. 2008
    ..The appearing of cutaneous metastasis is a negative prognostic factor since all the patients here described died within one year from the diagnosis of cutaneous metastases...
  25. pmc Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment
    David L Schwartz
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 74:1083-91. 2009
    ..To review institutional outcomes for patients treated for differentiated thyroid cancer with postoperative conformal external beam radiotherapy (EBRT)...
  26. pmc Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:997-1005. 2011
    ..We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins...
  27. doi request reprint The successful use of sorafenib to treat pediatric papillary thyroid carcinoma
    Steven G Waguespack
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Thyroid 19:407-12. 2009
    ..Sorafenib is an orally administered multi-kinase inhibitor that has shown promise in the treatment of adults with advanced thyroid cancer, but it has not yet been studied in children with this disease...
  28. pmc Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies
    David S Hong
    Division of Cancer Medicine, Department of Investigational Therapeutics Phase 1 Program, Unit 455, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 15:7061-8. 2009
    ....
  29. pmc Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hepatology 49:1563-70. 2009
    ..Experimental investigations are necessary for thorough assessment of the relationship between thyroid disorders and HCC...
  30. pmc Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009
    ..Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed...
  31. doi request reprint Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma
    Gary L Clayman
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 31:1152-63. 2009
    ....
  32. ncbi request reprint Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surgery 134:946-54; discussion 954-5. 2003
    ..We retrospectively compared preoperative transcutaneous ultrasonography and physical examination (PE) results in the detection of local-regional metastases (lymph node and soft tissue) in patients with thyroid cancer...
  33. ncbi request reprint Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship
    Linwah Yip
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Arch Surg 138:409-16; discussion 416. 2003
    ..Subtypes are defined by the presence or absence of pheochromocytomas, hyperparathyroidism, and characteristic clinical stigmas. We hypothesize that specific RET mutations correlate with the MEN 2 phenotype and aggressiveness of MTC...
  34. ncbi request reprint Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients
    Guido M Sclabas
    Department of Surgical Oncology, Houston, TX 77030, USA
    Am J Surg 186:702-9; discussion 709-10. 2003
    ..False-positive, false-negative, and indeterminate fine-needle aspiration (FNA) biopsy results complicate the management of patients with thyroid nodules...
  35. doi request reprint Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy
    Aarti Bhatia
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 32:829-36. 2010
    ..The aim of this study was to review institutional outcomes for anaplastic thyroid cancer treated with conformal 3-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT)...
  36. ncbi request reprint Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis
    N F Esnaola
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Tex. 77030-4009, USA
    Surgery 130:921-30. 2001
    ..CONCLUSIONS: Total thyroidectomy maximized quality-adjusted life expectancy in low- and high-risk patients with PTC...
  37. ncbi request reprint RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Thyroid 15:531-44. 2005
    ..Recommendations on the timing of prophylactic thyroidectomy and the extent of surgery are based upon a model that utilizes genotype- phenotype correlations to stratify mutations into three risk levels...
  38. doi request reprint Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study
    Grace L Smith
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 31:1031-8. 2009
    ..In patients with head and neck cancer, radiation treatment (RT) is a risk factor for hypothyroidism. However, the specific magnitude of risk after RT in older patients is not known...
  39. ncbi request reprint Parathyroid carcinoma: a 22-year experience
    Naifa L Busaidy
    joint Baylor College of Medicine The University of Texas M D Anderson Cancer Center Training Program in Endocrinology, Diabetes, and Metabolism, Houston, Texas, USA
    Head Neck 26:716-26. 2004
    ..Treatment strategies generally derive from clinical and anecdotal experiences. We report our experience with this entity...
  40. ncbi request reprint Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer
    Libero Santarpia
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    J Clin Endocrinol Metab 93:278-84. 2008
    ..The Ras/Raf-MAPK and the phosphatidylinositol 3-kinase/Akt signaling pathways play critical roles in DTC tumorigenesis, but their roles in the pathogenesis of ATC are poorly defined...
  41. ncbi request reprint New approaches to therapy of thyroid malignancies
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Adv Hematol Oncol 5:539-41. 2007
  42. ncbi request reprint Adenocarcinoma of the salivary gland metastatic to the pituitary gland: case report
    I E McCutcheon
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Neurosurgery 48:1161-5; discussion 1165-6. 2001
    ..A case of metastasis to the pituitary gland from a ductal adenocarcinoma of the salivary gland is presented. Metastasis to this site is rare, and a salivary gland source has never previously been described...
  43. ncbi request reprint Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification
    Danielle D Elliott
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 39:15-20. 2008
    ..We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy...
  44. ncbi request reprint Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma
    Farah Y Ghori
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Thyroid 12:1009-16. 2002
    ..Income and gender may affect stage at initial disease presentation and may be risk factors affecting eventual clinical outcomes...
  45. doi request reprint Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer
    Libero Santarpia
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 31:419-23. 2009
    ..Medullary thyroid cancer (MTC) commonly metastasizes to lymph nodes in the central and lateral neck, but spread to distant organs also occurs, typically involving lung, liver, and bone. Metastases to pituitary gland are rare for this tumor...
  46. ncbi request reprint Potential role for intraoperative gamma probe identification of normal parathyroid glands
    Lee C Pederson
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Surg 186:711-7. 2003
    ..Patients undergoing central neck surgery are at risk for hypoparathyroidism. We hypothesized that gamma probe identification of sestamibi-labeled parathyroid glands might help maximize parathyroid preservation...
  47. ncbi request reprint Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides
    Farah Ghori
    Department of Dermatology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 91:2205-8. 2006
    ..Denileukin diftitox binds to the high-affinity IL-2 receptor on the cell surface, and it is internalized by endocytosis and enzymatically cleaved. The cytotoxic A-fragment of the toxin inhibits protein synthesis and causes cell death...
  48. doi request reprint Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma
    Libero Santarpia
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Hum Pathol 40:827-33. 2009
    ..The effect of this mutation on the structural formation of the protein is highlighted. Our results confirm the infrequency of BRAF (V600E) mutation in FVPTC and identify a novel (A598V) mutation of this gene...
  49. ncbi request reprint Genotype-phenotype analysis in multiple endocrine neoplasia type 1
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Surg 137:641-7. 2002
    ..The syndrome demonstrates variable expressivity and considerable genetic heterogeneity. Patient data were examined for possible associations between genotype and phenotype...
  50. doi request reprint Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma
    Libero Santarpia
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:2974-83. 2010
    ..Defining these alterations may lead to the identification of diagnostic and biologic markers...
  51. doi request reprint Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory
    Ibrahima Gning
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Oncology 76:59-68. 2009
    ..The M. D. Anderson Symptom Inventory (MDASI) and its modules measure common symptoms related to cancer and its treatment. We report the development and initial validation of the MDASI-Thyroid Cancer module (MDASI-THY)...
  52. ncbi request reprint Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 30:1371-7. 2003
    ..It is quite possible that "stunning" from the radioiodine administered in the initial uptake study inhibited the subsequent uptake of radioiodine by the remnant lesions in the second uptake study...
  53. ncbi request reprint Outcomes of patients with differentiated thyroid carcinoma following initial therapy
    Jacqueline Jonklaas
    Georgetown University Medical Center, Washington, DC 20007, USA
    Thyroid 16:1229-42. 2006
    ..We were unable to show any impact, positive or negative, of specific therapies in stage I patients...
  54. ncbi request reprint Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects
    Wendy M Golden
    Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, Building RC 1 South Tower, MS 8106 12801 East 17th Avenue, PO Box 6511, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 92:124-30. 2007
    ..The influence of rexinoids on thyroid function in healthy subjects is not clear...
  55. ncbi request reprint A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal
    Pamela R Schroeder
    Johns Hopkins Medical Institutions, Division of Endocrinology and Metabolism, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 91:878-84. 2006
    ..Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal...
  56. ncbi request reprint Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal
    Heribert Hänscheid
    Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg, D 97080 Wurzburg, Germany
    J Nucl Med 47:648-54. 2006
    ..7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented...
  57. ncbi request reprint Phase II study of celecoxib in metastatic differentiated thyroid carcinoma
    Ewa Mrozek
    Division of Hematology, Departments of Internal Medicine, The Ohio State University Thyroid Cancer Unit, The Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio 43210, USA
    J Clin Endocrinol Metab 91:2201-4. 2006
    ..There is increased cyclooxygenase-2 (COX-2) expression in malignant thyroid nodules compared with nonneoplastic and benign thyroid tissue...
  58. ncbi request reprint Thyroid carcinoma
    Steven I Sherman
    University of Texas M D Anderson Cancer Center, USA
    J Natl Compr Canc Netw 3:404-57. 2005
  59. ncbi request reprint Subacute thyroiditis causing thyroid storm
    Steven I Sherman
    Thyroid 17:283. 2007
  60. ncbi request reprint Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma
    Steven I Sherman
    J Clin Endocrinol Metab 87:4059-62. 2002
  61. ncbi request reprint Management guidelines for patients with thyroid nodules and differentiated thyroid cancer
    David S Cooper
    Sinai Hospital of Baltimore and Johns Hopkins University School of Medicine, MD, USA
    Thyroid 16:109-42. 2006
  62. ncbi request reprint Thyroid carcinoma
    Steven I Sherman
    The University of Texas M D Anderson Cancer Center, USA
    J Natl Compr Canc Netw 5:568-621. 2007